Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility Dose Escalation Study for Evaluation of RT-310 for Treatment of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)

NCT06136819 is registered in ClinicalTrials.gov with Resurge Therapeutics Inc. as lead sponsor.

NCT NCT06136819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06136819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility Dose Escalation Study for Evaluation of RT-310 for Treatment of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
Lead sponsor
Resurge Therapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 19, 2024
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bph (benign prostatic hyperplasia), lower urinary tract symptoms